Ascendis Pharma A/S Stock

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
135.1 USD -1.71% Intraday chart for Ascendis Pharma A/S +3.60% +7.26%
Sales 2024 * 443M 481M Sales 2025 * 719M 779M Capitalization 7.14B 7.75B
Net income 2024 * -285M -309M Net income 2025 * 8M 8.68M EV / Sales 2024 * 17.1 x
Net Debt 2024 * 433M 470M Net Debt 2025 * 361M 392M EV / Sales 2025 * 10.4 x
P/E ratio 2024 *
-25.4 x
P/E ratio 2025 *
2,574 x
Employees 879
Yield 2024 *
-
Yield 2025 *
-
Free-Float 10.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.71%
1 week+3.60%
1 month-2.41%
3 months-8.57%
6 months+34.52%
Current year+7.26%
More quotes
1 week
125.87
Extreme 125.87
143.76
1 month
116.63
Extreme 116.625
143.99
Current year
116.63
Extreme 116.625
161.00
1 year
85.08
Extreme 85.0801
161.00
3 years
61.58
Extreme 61.5791
178.71
5 years
61.58
Extreme 61.5791
183.98
10 years
11.92
Extreme 11.92
183.98
More quotes
Managers TitleAgeSince
Founder 65 06-08-31
Director of Finance/CFO 50 16-08-07
Chief Tech/Sci/R&D Officer 50 20-04-30
Members of the board TitleAgeSince
Founder 65 06-08-31
Chairman 51 14-10-31
General Counsel 53 07-12-31
More insiders
Date Price Change Volume
24-05-31 135.1 -1.71% 587,045
24-05-30 137.4 +3.73% 511,857
24-05-29 132.5 +4.07% 570,368
24-05-28 127.3 -2.36% 153,794
24-05-24 130.4 +0.75% 250,225

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
124.6 EUR
Average target price
169.5 EUR
Spread / Average Target
+36.08%
Consensus